Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pioglitazone
Drug ID BADD_D01777
Description Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence.[L11416] The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose[L11416] via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ).[A19757] PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis.[A19759] Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus.[L11461]
Indications and Usage Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [FDA Label].
Marketing Status Prescription
ATC Code A10BG03
DrugBank ID DB01132
KEGG ID D08378
MeSH ID D000077205
PubChem ID 4829
TTD Drug ID D03OFF
NDC Product Code 57237-219; 68071-4964; 50090-2390; 70771-1021; 68071-4959; 50090-4605; 50090-4556; 61919-781; 50090-4780; 50090-2401; 68071-2264; 11532-0011; 68071-2373; 0781-5420; 71335-1298; 68382-306; 70518-2609; 43547-427; 64764-451; 71335-1137; 68071-5155; 68382-307; 60687-391; 33342-056; 57237-221; 72189-293; 68788-7514; 0093-7273; 50090-4586; 70771-1022; 71335-1385; 33342-055; 50090-1321; 68382-308; 16729-020; 70518-2129; 64764-151; 16729-022; 68071-1621; 68788-7511; 0093-7271; 53002-2757; 16729-021; 68071-2437; 70518-2431; 68788-7989; 33342-054; 71335-1659; 0093-7272; 71335-1333; 53002-2755; 71335-0088; 72189-105; 0781-5422; 71335-1759; 70771-1023; 43547-428; 53002-2756; 11532-0013; 68071-5080; 0904-7096; 64764-301; 71610-495; 0904-7090; 70934-619; 0781-5421; 68071-2495; 11532-0012; 57237-220; 43547-426
Synonyms Pioglitazone | 5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione | U 72107A | U72,107A | U-72107A | U72107A | AD 4833 | AD-4833 | AD4833 | Pioglitazone Hydrochloride | Actos
Chemical Information
Molecular Formula C19H20N2O3S
CAS Registry Number 111025-46-8
SMILES CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Femoral neck fracture15.08.03.002; 12.04.01.0020.000384%Not Available
Femur fracture15.08.03.003; 12.04.01.003--Not Available
Flatulence07.01.04.002--
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Fracture15.08.02.001; 12.04.02.001--
Gait disturbance17.02.05.016; 08.01.02.002--
Gastric cancer16.13.03.001; 07.21.02.0010.000201%Not Available
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Generalised oedema14.05.06.007; 08.01.07.0040.000577%
Glycosuria20.02.01.005--
Glycosylated haemoglobin decreased13.02.02.012--Not Available
Haematocrit decreased13.01.05.001--Not Available
Haematuria24.07.01.047; 20.02.01.0060.004997%
Blood urine present13.13.02.0020.001730%Not Available
Haemoglobin decreased13.01.05.003--Not Available
Headache17.14.01.001--
Hepatic failure09.01.03.002--
Hepatitis09.01.07.004--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkalaemia14.05.03.001--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hyperthyroidism14.11.01.011; 05.02.02.001--
Hypoaesthesia17.02.06.023--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypoglycaemic coma14.06.03.004; 05.06.03.004; 17.02.09.0050.000577%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 8 Pages